CarsonAllaria Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

CarsonAllaria Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-160	Closed	-$755	–	324
2025 Q2	$755	Hold	160	–	–	﹤0.01%	342
2025 Q1	$734	Hold	160	–	–	﹤0.01%	352
2024 Q4	$766	Hold	160	–	–	﹤0.01%	333
2024 Q3	$750	Hold	160	–	–	﹤0.01%	371
2024 Q2	$904	Hold	160	–	–	﹤0.01%	352
2024 Q1	$658	Hold	160	–	–	﹤0.01%	375
2023 Q4	$675	Hold	160	–	–	﹤0.01%	339
2023 Q3	$691	Hold	160	–	–	﹤0.01%	344
2023 Q2	$1.05K	Hold	160	–	–	﹤0.01%	351
2023 Q1	$1.09K	Hold	160	–	–	﹤0.01%	331
2022 Q4	$1K	Hold	160	–	–	﹤0.01%	333
2022 Q3	$2K	Hold	160	–	–	﹤0.01%	288
2022 Q2	$2K	Hold	160	–	–	﹤0.01%	288
2022 Q1	$2K	Hold	160	–	–	﹤0.01%	308
2021 Q4	$3K	Buy	+160	New	+$2.79K	﹤0.01%	307

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

CarsonAllaria Wealth Management's VNDA Position: Q3 2025 in Review

CarsonAllaria Wealth Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2025, closing a stake of 160 shares — an estimated $755 sold.

CarsonAllaria Wealth Management first reported a position in VNDA in Q4 2021 and held it in 15 quarters. The position peaked at $3K in Q4 2021. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.

CarsonAllaria Wealth Management reported no remaining Vanda Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
CarsonAllaria Wealth Management sold 160 Vanda Pharmaceuticals shares in Q3 2025, an estimated $755.
CarsonAllaria Wealth Management first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 15 quarters.
CarsonAllaria Wealth Management's Vanda Pharmaceuticals position peaked at $3K in Q4 2021.
150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2025, filed 28 Oct 2025.